Early-Stage Biopharma Alliance Up-Fronts Rising; Late State Alliance Up-Fronts Falling?
This article was originally published in Start Up
Executive Summary
Common sense tells us that a later stage asset - in all its de-risked loveliness - is more valuable than, say, a preclinical or Phase I asset. But in 2009, up-front deal values for preclinical and Phase I products continued.